The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study

• Published in: Future oncology (London, England) Vol. 19; no. 23; pp. 1601 - 1611
• Main Authors: Marmorino, Federica, Faggioni, Lorenzo, Rossini, Daniele, Gabelloni, Michela, Goddi, Antonio, Ferrer, Loïc, Conca, Veronica, Vargas, Jennifer, Biagiarelli, Fiammetta, Daniel, Francesca, Carullo, Martina, Vetere, Guglielmo, Granetto, Cristina, Boccaccio, Chiara, Cioni, Dania, Antonuzzo, Lorenzo, Bergamo, Francesca, Pietrantonio, Filippo, Cremolini, Chiara, Neri, Emanuele
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.07.2023
• Subjects: first-line chemotherapy plus bevacizumab; liver-limited metastatic colorectal cancer; prognostic factor; radiomic features; TRIBE2 study; radiomic features; liver-limited metastatic colorectal cancer; prognostic factor; first-line chemotherapy plus bevacizumab; TRIBE2 study
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2023-0406

Evaluating the prognostic role of radiomic features in liver-limited metastatic colorectal cancer treated with first-line therapy at baseline and best response among patients undergoing resection. Among patients enrolled in TRIBE2 ( ), the association of clinical and radiomic data, extracted by SOPHiA-DDM™ with progression-free and overall survival (OS) in the overall population and with disease-free survival/postresection OS in those undergoing resection was investigated. Among 98 patients, radiomic parameters improved the prediction accuracy of our model for OS (area under the curve: 0.83; sensitivity: 0.85; specificity: 0.73; accuracy: 0.78), but not progression-free survival. Of 46 resected patients, small-distance high gray-level emphasis was associated with shorter disease-free survival and high gray-level zone emphasis/higher kurtosis with shorter postresection OS. Radiomic features should be implemented as tools of outcome prediction for liver-limited metastatic colorectal cancer. In colorectal liver metastases, radiomics could be a valid tool for predicting prognosis in patients receiving first-line treatment and for stratification of patients based on the risk of relapse after curative resection.